HHM Wealth Advisors’s Briacell Therapeutics BCTX Stock Holding History

HHM Wealth Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20	Hold	6	–	–	﹤0.01%	892
2026 Q1	$26	Hold	6	–	–	﹤0.01%	868
2025 Q4	$43	Hold	6	–	–	﹤0.01%	840
2025 Q3	$66	Sell	6 -1	-14%	-$11	﹤0.01%	844
2025 Q2	$195	Hold	7	–	–	﹤0.01%	843
2025 Q1	$241	Hold	7	–	–	﹤0.01%	894
2024 Q4	$565	Hold	7	–	–	﹤0.01%	911
2024 Q3	$1.24K	Hold	7	–	–	﹤0.01%	722
2024 Q2	$1.14K	Buy	+7	New	+$1.98K	﹤0.01%	729

Other funds holding BCTX

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

SSA

SSA Swiss Advisors Zurich $266M AUM 24.57% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

HHM Wealth Advisors's BCTX Position: Q2 2026 in Review

HHM Wealth Advisors held its Briacell Therapeutics (BCTX) position steady in Q2 2026 at 6 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #892.

HHM Wealth Advisors first reported a position in BCTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.24K in Q3 2024. 6 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

HHM Wealth Advisors held 6 shares of Briacell Therapeutics worth $20 as of Q2 2026.
HHM Wealth Advisors left its Briacell Therapeutics share count unchanged in Q2 2026.
Briacell Therapeutics made up ﹤0.01% of HHM Wealth Advisors's portfolio in Q2 2026, its #892 holding.
HHM Wealth Advisors first reported a position in Briacell Therapeutics in Q2 2024 and has held it in 9 quarters since.
HHM Wealth Advisors's Briacell Therapeutics position peaked at $1.24K in Q3 2024.
6 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on HHM Wealth Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.